|1.||Gheorghiade, Mihai: 10 articles (05/2008 - 03/2002)|
|2.||O'Connor, Christopher M: 7 articles (05/2008 - 03/2002)|
|3.||McNamara, Patrick J: 6 articles (01/2016 - 06/2006)|
|4.||Califf, Robert M: 6 articles (05/2008 - 03/2002)|
|5.||Leimberger, Jeffrey D: 6 articles (05/2008 - 01/2003)|
|6.||Felker, G Michael: 6 articles (12/2006 - 01/2003)|
|7.||Cheung, Po-Yin: 5 articles (08/2015 - 07/2008)|
|8.||Wang, Shih-Min: 5 articles (07/2013 - 03/2005)|
|9.||Liu, Ching-Chuan: 5 articles (07/2013 - 03/2005)|
|10.||Adams, Kirkwood F: 5 articles (05/2008 - 03/2002)|
09/01/1994 - "Milrinone is an inotropic and vasodilator agent proven to be effective in the treatment of heart failure. "
01/01/1987 - "Milrinone, a potent positive inotropic and vasodilating agent, has shown promise in the clinical treatment of congestive heart failure, but significant controversy about its mechanism of action exists. "
09/01/1983 - "Milrinone is a potent cardioactive agent which should be beneficial in the treatment of acute and chronic congestive heart failure."
08/01/2000 - "Although phosphodiesterase 3 (PDE3) activity is abundant in human cardiovascular tissues, and acute PDE3 inhibition, with agents such as milrinone, was beneficial in heart failure patients, prolonged treatments were associated with time-dependent reductions in hemodynamic effects and increased mortality. "
02/01/1993 - "Improved hemodynamic effects and the good safety/acceptability of the drug indicate that milrinone is a treatment of choice in cardiac failure."
|2.||Pulmonary Hypertension (Ayerza Syndrome)
09/01/2010 - "Although it is a very small sample of patients, we conclude that the combination of inhaled and intravenous milrinone could be an effective treatment of secondary pulmonary hypertension in high-risk cardiac valve surgery patient. "
12/01/2005 - "After inhalation for ten minutes, milrinone induced a significant reduction of mean pulmonary arterial pressure (32.7 +/- 9.1 vs 37.7 +/- 7.5 mmHg, P = 0.01), pulmonary vascular resistance index (296 +/- 150 vs 396 +/- 151 dyn.sec(-1).cm(-5).m(2), P = 0.02) and transpulmonary gradient (10.6 +/- 5.5 vs 15 +/- 4.9, P = 0.01) only in patients with significant pulmonary hypertension. "
04/01/2015 - "Milrinone has been proposed as an effective treatment for pulmonary hypertension (PH) and right ventricular (RV) dysfunction. "
04/01/2000 - "We conclude that milrinone is effective in the management of pulmonary hypertension following CPB in children who underwent TOF repair."
01/01/2013 - "An open label study of milrinone in neonates with persistent pulmonary hypertension of the newborn was conducted. "
01/01/2015 - "High dose IV milrinone therapy for symptomatic DCI after SAH can lead to rapid neurological improvement with dramatic early angiographic improvement of cerebral vasospasm. "
02/01/1997 - "Milrinone is effective in preventing chronic cerebral vasospasm in a canine model of experimental chronic cerebral vasospasm. "
02/01/2011 - "Intra-arterial milrinone was a safe and effective treatment of cerebral vasospasm following aneurysmal SAH."
01/01/2009 - "The objective of this study was to evaluate the safety and efficacy of intra-arterial Milrinone in patients with symptomatic refractory cerebral vasospasm. "
02/01/1997 - "The purpose of the present study was to investigate the effect of milrinone on chronic experimental cerebral vasospasm. "
|4.||Hypotension (Low Blood Pressure)
06/01/2006 - "Infants who received milrinone did not develop systemic hypotension; in fact, there was a nonsignificant trend toward improved blood pressure. "
02/01/2007 - "Systemic arterial hypotension and vasopressor requirements with milrinone use at inotropic doses were not observed at the doses used for the study. "
09/01/2014 - "Dose reduction of milrinone due to hypotension occurred in only 4 admissions (0.5%). "
08/01/2014 - "We conclude that milrinone is useful for induced hypotension in elderly patients during spinal surgery."
08/01/2014 - "To determine the effect of milrinone on induced hypotension during spinal surgery in elderly patients. "
06/01/1991 - "Control ergometry revealed ischemia; however, during exercise with intravenous milrinone, ischemia was eliminated. "
07/01/1999 - "To determine the role of beta adrenergic stimulation before ischemia, a dose-response study was undertaken with isoprotelenol and milrinone at 37 degrees C. "
02/01/2014 - "In group M (n = 10), milrinone (5 µg/kg) was administered before ischemia. "
01/01/2009 - "During ischemia, nebulized milrinone (n = 6) or saline (n = 6) was inhaled. "
03/01/2008 - "We demonstrated that the pre-emptive administration of milrinone before ischemia was associated with less ischemic hemodynamic effects, without worsening the ischemic metabolic process. "
|3.||Type 3 Cyclic Nucleotide Phosphodiesterases
|6.||Nitroprusside (Sodium Nitroprusside)
|8.||Brain Natriuretic Peptide (Natrecor)
|9.||Vasodilator Agents (Vasodilators)
|10.||N(1)-methyl-2-lysergic acid diethylamide (MIL)
|2.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|4.||Off-Pump Coronary Artery Bypass (Coronary Artery Bypass, Off Pump)